Cochlear Ltd. shares experienced their steepest decline in more than three decades after the Australian hearing-implant maker cut its fiscal year profit guidance. The dramatic selloff signals investor alarm over reduced expectations for the medical device company, which dominates the global cochlear implant market.

When a market leader like Cochlear trims its profit outlook, it typically triggers concerns about underlying business conditions. The severity of the reaction—marking the company's worst single-day performance in over 30 years—suggests analysts and investors had been counting on stronger results. The guidance cut raises questions about what factors are weighing on the company's earnings trajectory.

The plunge reverberates across the medical device sector, where Cochlear often sets the tone for industry performance. Investors in healthcare stocks will watch closely for any additional signals about the company's near-term outlook, as the selloff reflects broader market caution about the hearing-implant maker's growth prospects.